Agentic AI has the potential to reshape not just healthcare, but the very foundations of biological research. By allowing autonomous systems to explore the unknown, we may unlock new levels of ...

Owkin has announced a partnership with AstraZeneca to create an AI gBRCA pre-screening solution designed to identify ...

Utilizing Owkin’s expansive data network and cutting-edge AI, this solution optimizes pre-screening for gBRCA mutations in breast cancer directly from digitized H&E pathology slides The solution ...

A mesothelioma prognostic model from medical machine learning firm Owkin has been showcased in the journal Nature, and is being used to help further drug research into the often fatal disease.

Owkin is simultaneously releasing two other open-source projects: FLamby, a federated learning model-ready dataset that researchers can use to develop models before training them on other data ...

A Research Use Only (RUO) version will launch on Roche’s navify® Digital Pathology enterprise software, an application for the pathologist’s workflow aimed to support pathologists and ...

Sanofi has made numerous investments in AI, inking pacts with partners such as Owkin and Exscientia. The French major has ...

Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca ...

PARIS–(BUSINESS WIRE)–Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug ...